Hamilton, Bermuda – July 25 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced that it will report its 2018 second quarter financial results on Tuesday, August 7, 2018. The full filing stated:
DUBLIN,July24,2018/PRNewswire/--JazzPharmaceuticalsplc(Nasdaq:JAZZ)todayannouncedthatitwill reportits2018second quarterfinancialresults onTuesday,August7, 2018,afterthe closeof thefinancial markets.Company managementwill host alive audiowebcastimmediatelyfollowingtheannouncementat4:30p.m.EDT/9:30p.m.ISTtodiscusssecondquarter2018financialresultsandprovideabusinessandfinancialupdate.
Interestedpartiesmay accessthe liveaudiowebcast viatheInvestorssectionof theJazzPharmaceuticalswebsiteathttp://www.jazzpharmaceuticals.com.Pleaseconnecttothewebsitepriorto the start of theconference call to ensure adequatetime for any software downloadsthatmay benecessary tolisten tothe webcast.A replayof thewebcastwill bearchived onthe websitefor at leastone week.
U.S. Dial-In Number:+1855 353 7924InternationalDial-InNumber:+15033436056Passcode:4989706
Areplayof theconferencecall willbeavailable throughAugust 14,2018and accessiblethroughoneofthefollowingtelephonenumbers,usingthepasscodebelow:
ReplayU.S. Dial-InNumber:+1855 8592056
ReplayInternationalDial-InNumber:+14045373406
Passcode:4989706
JazzPharmaceuticalsplc(Nasdaq:JAZZ)isaninternationalbiopharmaceuticalcompanyfocusedonimprovingpatients’livesbyidentifying,developingandcommercializingmeaningfulproductsthataddressunmetmedicalneeds.The companyhasadiverseportfolioof productsandproductcandidateswith afocusinthe areasofsleep andhematology/oncology.Inthese areas,JazzPharmaceuticalsmarketsXyrem®(sodiumoxybate)oralsolution,Erwinaze®(asparaginaseErwiniachrysanthemi),Defitelio®(defibrotidesodium)andVyxeos®(daunorubicinandcytarabine)liposomeforinjectionintheU.S.andmarketsErwinase®andDefitelio®(defibrotide)incountriesoutsidetheU.S.Forcountry-specificproductinformation,pleasevisit http://www.jazzpharmaceuticals.com/products.Formoreinformation,pleasevisit http://www.jazzpharmaceuticals.com/andfollowusonTwitterat@JazzPharma.
KatheeLittrell
VicePresident,InvestorRelationsIreland,+3531 6347887
U.S., +1 650 496 2717
JacquelineKirby
VicePresident,CorporateAffairs&GovernmentRelationsIreland,+3531 6972141
U.S., +1 215 867 4910
Disclaimer and Privacy Policy Complaints Policy
Copyright © 2024 by Bermuda Stock Exchange. All rights reserved!
Questions or requests for information can be emailed to info@bsx.com